Exosomes of Whartons’ jelly mesenchymal stem cell reduce the NOX genes in TGF-β-induced hepatic fibrosis

سال انتشار: 1401
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 205

فایل این مقاله در 6 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-25-12_011

تاریخ نمایه سازی: 25 آبان 1401

چکیده مقاله:

Objective(s): Activated cells which are called star-shaped cells, are some of the key factors in the development of liver fibrosis. Activation of NADPH oxidase (NOX) is associated with increased HSCs activity and progression of hepatic fibrosis. In this study, the effects of human exosomes derived from WJ-MSCs on NOX۱, NOX۲, and NOX۴ gene expression in TGF-β-induced hepatic fibrosis were investigated.Materials and Methods: LX۲ cell line was treated with ۲ ng/ml TGF-β for ۲۴ hr, in order to induce liver fibrosis after starvation. In the next step, the cells were treated with several concentrations of the exosomes derived from WJ-MSCs (۱۰, ۲۰, ۳۰, ۴۰, and ۵۰ μg/ml). Finally, Smad۳C phosphorylated protein expression level and NOX۱, NOX۲, and NOX۴ gene expression levels were measured.Results: The results demonstrated that the level of NOX۱, NOX۲, and NOX۴ mRNA expressions decreased significantly during ۲۴ hrs at concentrations of ۴۰ and ۵۰ μg/ml of WJ-MSCs exosomes in TGF-β-induced-HSCs. The p-Smad۳C proteins were significantly decreased (fold change: ۱.۸۳, P-value<۰.۰۵) after exposure to WJ-MSC-derived exosomes. Conclusion: Treatment with exosomes prevents further activation of HSCs by inhibiting the level of Smad۳C phosphorylation. The experimental data of our study suggested that in liver fibrosis, the protection of HSCs activation against TGF-β by inhibiting the NOX pathway via human exosomes of WJ-MSCs is extremely important. It needs further research as a treatment method.

کلیدواژه ها:

Exosome ، HSCs/LX۲ ، Liver fibrosis ، TGF β/Smad۳C and NOXs ، WJ-MSCs

نویسندگان

Reza Afarin

Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Tahereh Behdarvand

Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Elham Shakerian

Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Samaneh Salehipour Bavarsad

Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Mojtaba Rashidi

Department of Clinical Biochemistry, Faculty of Medicine, Jundishapour University of Medical Sciences, Ahvaz, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J ...
  • Bataller R, Brenner DA. Liver fibrosis. J Clin Invest ۲۰۰۵;۱۱۵:۲۰۹-۲۱۸ ...
  • Kawaratani H, Tsujimoto T, Douhara A, Takaya H, Moriya K, ...
  • Pinzani M, Marra F. Cytokine receptors and signaling in hepatic ...
  • Koyama Y, Xu J, Liu X, Brenner DA. New developments ...
  • Chang Y, Li H. Hepatic antifibrotic pharmacotherapy: Are we approaching ...
  • Mortezaee K. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) and ...
  • Cui W, Matsuno K, Iwata K, Ibi M, Matsumoto M, ...
  • Yoshida K, Murata M, Yamaguchi T, Matsuzaki K. TGF-β/Smad signaling ...
  • Liang S, Kisseleva T, Brenner DA. The role of NADPH ...
  • Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, ...
  • Huang F, Chen Y-G. Regulation of TGF-β receptor activity. Cell ...
  • Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic ...
  • Gressner A, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis ...
  • Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF‐β ...
  • Balta C, Herman H, Boldura OM, Gasca I, Rosu M, ...
  • Zhang Z, Wang F-S. Stem cell therapies for liver failure ...
  • Lou G, Chen Z, Zheng M, Liu Y. Mesenchymal stem ...
  • Asgarpour K, Shojaei Z, Amiri F, Ai J, Mahjoubin-Tehran M, ...
  • Puig-Pijuan T, de Godoy MA, Pinheiro Carvalho LR, Bodart-Santos V, ...
  • Yu B, Zhang X, Li X. Exosomes derived from mesenchymal ...
  • Nojehdehi S, Hashemi SM, Hesampour A. Isolation and characterization of ...
  • Gowen A, Shahjin F, Chand S, Odegaard KE, Yelamanchili SV. ...
  • Shibata N, Watanabe T, Okitsu T, Sakaguchi M, Takesue M, ...
  • Shi Y-F, Zhang Q, Cheung P-Y, Shi L, Fong C-C, ...
  • Sokolova V, Ludwig A-K, Hornung S, Rotan O, Horn PA, ...
  • Van der Pol E, Coumans F, Varga Z, Krumrey M, ...
  • Mohammadzadeh G, Afarin R, Bavarsad SS, Aslani F, Zadeh SA, ...
  • Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, ...
  • Abbaszadeh H, Ghorbani F, Derakhshani M, Movassaghpour AA, Yousefi M, ...
  • Tsai PC, Fu TW, Chen YMA, Ko TL, Chen TH, ...
  • Parekkadan B, van Poll D, Megeed Z, Kobayashi N, Tilles ...
  • Qiao H, Zhou Y, Qin X, Cheng J, He Y, ...
  • Weiskirchen R. Hepatoprotective and anti-fibrotic agents: It’s time to take ...
  • Paik Y-H, Kim J, Aoyama T, De Minicis S, Bataller ...
  • Lan T, Kisseleva T, Brenner DA. Deficiency of NOX۱ or ...
  • Paik YH, Iwaisako K, Seki E, Inokuchi S, Schnabl B, ...
  • Zhang W, Liu R, Chen Y, Wang M, Du J. ...
  • Liu M, Huang Q, Zhu Y, Chen L, Li Y, ...
  • Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, ...
  • Zhang G, Zou X, Miao S, Chen J, Du T, ...
  • Lin K-C, Yip H-K, Shao P-L, Wu S-C, Chen K-H, ...
  • Chen L, Wang Y, Pan Y, Zhang L, Shen C, ...
  • Sart S, Song L, Li Y. Controlling redox status for ...
  • نمایش کامل مراجع